Specificities of antibodies used in this study
| Antibody . | Free pro-αIIb . | Free β3 . | Pro-αIIbβ3 . | αIIbβ3 . | Domain* . | Amino acid residues* . | References . |
|---|---|---|---|---|---|---|---|
| 10E5 | − | NA | +++ | +++ | Cap | 77-82, 149, 158, 206, 208, 213-215 | Xiao et al,15 Coller et al17 |
| CA3 | ++ | NA | +++ | +++ | Unknown | Unknown | Commercial |
| Anti-V5 | +++ | NA | +++ | +++ | C-terminal tag | Unknown | Southern et al26 |
| PMI-1 | ± | NA | + | + | Calf-2 | 844-859 | Shadle et al,18 Ginsberg et al,21 Frelinger et al,27 Frelinger et al28 |
| B1B5 | ++ | NA | + | + | Calf-2 | 860-993 | Silver et al,8 Peterson et al29 |
| Anti-αIIb (H-160) | + | NA | − | − | Calf-2 | 847-859,† 860-1006 | Commercial |
| 7E3 | NA | − | +++ | +++ | β-A | 177-184, 125, 129 | Coller,19 Artoni et al30 |
| 7H2 | NA | +++ | +++ | +++ | PSI | C13 | Kutok and Coller23 |
| AP3 | NA | +++ | +++ | +++ | PSI/Hybrid | 50,62 | Newman et al,20 Kouns et al,31 Peterson et al44 |
| AP5 | NA | +++ | + | − | PSI | 1-6 | Honda et al,25 Kekomaki et al32 |
| LIBS1 | NA | ++ | − | − | Unknown | Unknown | Frelinger et al22 |
| LIBS2 | NA | +++ | + | − | βTD | 602-690 | Frelinger et al,22 Kutok and Coller23 |
| LIBS6 | NA | ++ | − | − | EGF/βTD | 490-690 | Frelinger et al22 |
| PMI-2 | NA | ++ | − | − | Unknown | Unknown | Shadle et al,18 Frelinger et al28 |
| Antibody . | Free pro-αIIb . | Free β3 . | Pro-αIIbβ3 . | αIIbβ3 . | Domain* . | Amino acid residues* . | References . |
|---|---|---|---|---|---|---|---|
| 10E5 | − | NA | +++ | +++ | Cap | 77-82, 149, 158, 206, 208, 213-215 | Xiao et al,15 Coller et al17 |
| CA3 | ++ | NA | +++ | +++ | Unknown | Unknown | Commercial |
| Anti-V5 | +++ | NA | +++ | +++ | C-terminal tag | Unknown | Southern et al26 |
| PMI-1 | ± | NA | + | + | Calf-2 | 844-859 | Shadle et al,18 Ginsberg et al,21 Frelinger et al,27 Frelinger et al28 |
| B1B5 | ++ | NA | + | + | Calf-2 | 860-993 | Silver et al,8 Peterson et al29 |
| Anti-αIIb (H-160) | + | NA | − | − | Calf-2 | 847-859,† 860-1006 | Commercial |
| 7E3 | NA | − | +++ | +++ | β-A | 177-184, 125, 129 | Coller,19 Artoni et al30 |
| 7H2 | NA | +++ | +++ | +++ | PSI | C13 | Kutok and Coller23 |
| AP3 | NA | +++ | +++ | +++ | PSI/Hybrid | 50,62 | Newman et al,20 Kouns et al,31 Peterson et al44 |
| AP5 | NA | +++ | + | − | PSI | 1-6 | Honda et al,25 Kekomaki et al32 |
| LIBS1 | NA | ++ | − | − | Unknown | Unknown | Frelinger et al22 |
| LIBS2 | NA | +++ | + | − | βTD | 602-690 | Frelinger et al,22 Kutok and Coller23 |
| LIBS6 | NA | ++ | − | − | EGF/βTD | 490-690 | Frelinger et al22 |
| PMI-2 | NA | ++ | − | − | Unknown | Unknown | Shadle et al,18 Frelinger et al28 |
Plus signs indicate the ability of the antibody to immunoprecipitate the indicated molecular form, with a maximum rating of 3 pluses; NA, not applicable.
Narrowest amino acid sequence range to which the epitope has been localized.
Amino acid 859 is one of the candidate cleavage sites for the conversion of pro-αIIb to the 2-chain mature αIIb.